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Abstract
Objective: Maternal smoking during pregnancy is associated with fetal growth retardation. We examined whether a
common genetic variant at chromosome 15q25 (rs1051730), which is known to be involved in nicotine metabolism,
modifies the associations of maternal smoking with fetal growth characteristics.
Methods: This study was performed in 3,563 European mothers participating in a population-based prospective cohort
study from early pregnancy onwards. Smoking was assessed by postal questionnaires and fetal growth characteristics were
measured by ultrasound examinations in each trimester of pregnancy.
Results: Among mothers who did not smoke during pregnancy (82.9%), maternal rs1051730 was not consistently associated
with any fetal growth characteristic. Among mothers who continued smoking during pregnancy (17.1%), maternal
rs1051730 was not associated with head circumference. The T-allele of maternal rs1051730 was associated with a smaller
second and third trimester fetal femur length [differences 20.23 mm (95%CI 20.45 to 20.00) and 20.41 mm (95%CI 20.69
to 20.13), respectively] and a smaller birth length [difference 22.61 mm (95%CI 25.32 to 0.11)]. The maternal T-allele of
rs1051730 was associated with a lower third trimester estimated fetal weight [difference 233 grams (95%CI 255 to 210)],
and tended to be associated with birth weight [difference 238 grams (95%CI 289 to 13)]. This association persisted after
adjustment for smoking quantity.
Conclusions: Our results suggest that maternal rs1051730 genotype modifies the associations of maternal smoking during
pregnancy with impaired fetal growth in length and weight. These results should be considered as hypothesis generating
and indicate the need for large-scale genome wide association studies focusing on gene – fetal smoke exposure
interactions.
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Introduction
Maternal smoking during pregnancy is strongly associated with
increased risks of preterm birth or a small size for gestational age
at birth [1]. As compared to children of mothers who did not
smoke during pregnancy, those of mothers who smoked during
pregnancy have a 100 to 200 grams lower birth weight [1]. It has
been estimated that, in Western countries, 30 percent of children
with low birth weight can be explained by exposure to tobacco
smoke during pregnancy [2–3]. The effects of maternal smoking
on fetal growth differ between individuals. These differences in
effects might be explained by maternal genetic predisposition. A
recent genome wide association study meta-analysis identified a
common genetic variant, rs1051730, located within the 15q25
nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-
CHRNB4), to be associated with smoking quantity [4]. Smokers
with a risk allele (T-allele) of rs1051730 seem to have higher blood
levels of nicotine, compared to smokers without the T-allele [5].
Another study showed that among mothers who smoked during
pregnancy, each additional copy of the maternal T-allele of
rs1051730 resulted in a 28 grams lower birth weight in the
offspring [6], though this effect was not significant. These findings
suggest that rs1051730 might be a common genetic variant leading
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to an increased susceptibility of the adverse effects of maternal
smoking on fetal growth and development.
Therefore, we explored in a population-based prospective
cohort study among 3,563 European mothers, whether maternal
rs1051730 modifies the associations of maternal smoking during
pregnancy with fetal growth characteristics in different trimesters.
Results
In our population, 610 (17.1%) mothers continued smoking
during pregnancy (Table 1). Mean maternal age was 31.1 years.
As compared to mothers who did not smoke during pregnancy,
mothers who smoked during pregnancy were shorter, had higher
weight and were lower educated. Children of mothers who
smoked during pregnancy had a lower birth weight than children
of mothers who did not smoke. Distribution of maternal genotype
of rs1051730 was different between non-smokers and continued
smokers. Genotype was not associated with smoking quantity.
Subject characteristics per maternal genotype group among
continued smokers are given in Table S1.
In the total population, we did not observe associations of the
maternal T-allele of rs1051730 with fetal growth characteristics
(Table 2). Among mothers who continued smoking, we observed
non-significant tendencies toward smaller (fetal) head circumfer-
ence for each additional copy of the maternal T-allele of
rs1051730. The T-allele of maternal rs1051730 was associated
with a smaller second and third trimester fetal femur length
[differences 20.23 mm (95%CI 20.45 to 20.00) and 20.41 mm
(95%CI 20.69 to 20.13), respectively] and tended to be
associated with a smaller birth length [difference 22.61 mm
(95%CI 25.32 to 0.11)] (Table 2). For all fetal length measures,
we found a significant interaction between maternal smoking
status and maternal genotype of rs1051730 [Pinteraction,0.05].
Among mothers who smoked during pregnancy, the T-allele was
associated with a lower third trimester estimated fetal weight
[difference 232.7 grams (95%CI 255.4 to 210.0)], and tended to
be associated with lower birth weight [difference 238.1 grams
(95%CI 289.2 to 12.9)]. Among the mothers who smoked during
pregnancy, those who had a T/T genotype gave birth to children
with a birth weight that was 117 grams lower (95% CI 2229 to
24 grams), as compared to children whose mothers had a G/G
genotype. We found a significant interaction between maternal
smoking status and maternal genotype of rs1051730 for fetal
weight at all time points [Pinteraction,0.05].
In Figure 1, the results of maternal genotype of rs1051730 per
smoking status with longitudinal fetal growth patterns are
Table 1. Subject characteristics of the mothers per smoking status (n = 3,563)1.
Total Non-smokers Continued smokers
N=3,563 N=2,953 (82.9%) N=610 (17.1%)
Mother
Age (years) 31.1 (4.5) 31.4 (4.2) 29.7 (5.6)**
Gestational age at enrollment2 (weeks) 13.6 (10.1 to 23.2) 13.6 (10.2 to 22.9) 14.1 (9.5 to 29.4)**
Height (cm) 170.3 (6.5) 170.4 (6.5) 169.3 (6.5)**
Weight (kg) 70.2 (12.6) 70.0 (12.2) 71.2 (14.0)*
Body mass index (kg/m2) 24.2 (4.1) 24.1 (4.0) 24.8 (4.5)**
Parity (% nullipara) 59.8 60.4 57.4
Highest education finished (%)
Primary school 4.4 2.6 13.3**
Secondary school 38.5 33.7 62.5**
Higher education 57.1 63.8 24.2**
Alcohol consumption during pregnancy (% yes) 65.3 66.2 61.3*
Number of cigarettes smoked (%)
,5 per day NA NA 45.2
5–10 per day NA NA 32.7
.10 per day NA NA 22.0
Genotype (%)
G/G 45.4 46.3 41.0*
G/T 43.1 42.2 47.4*
T/T 11.6 11.5 11.6
Child
Gestational age at birth2 (weeks) 40.1 (35.6 to 42.3) 40.3 (35.8 to 42.3) 40.0 (34.8 to 42.3)**
Birth weight (grams) 3476 (558) 3514 (553) 3290 (546)**
Sex (% Boys) 49.6 49.1 52.5
1Values are means (SD) or percentages.
2Median (95% range).
Differences in distributions between groups were evaluated using a Student T-test for continuous variables and Chi-square tests for categorical variables.
*P-value,0.05;
**P-value,0.01.
doi:10.1371/journal.pone.0034584.t001
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presented as difference in standard deviation scores, adjusted for
gestational age and sex. This gives the relative effect in different
periods of pregnancy. All genotype categories of mothers who
smoked during pregnancy had smaller fetal head circumference,
length and weight measures, as compared to the mothers who did
not smoke during pregnancy. Among mothers who did not smoke
during pregnancy, the maternal T-allele of rs1051730 had a
positive effect on head circumference growth, but was not
significantly associated with length and weight growth. Among
mothers who smoked during pregnancy, the T-allele was
associated with the smallest head circumference, length and
weight growth. The effects seem to be larger for length and weight
than for head circumference. The specific coefficients of the
gestational age independent and dependent differences (interac-
tion smoke status, rs1051730 genotype and gestational age) for
these models are given in Table S2.
We performed several sensitivity analyses. First, results of the
analyses with a dominant genetic model are shown in Table S3.
Second, additional analyses showed that the fetal genotype of
rs1051730, was not associated with any fetal growth characteristic
after adjustment for the maternal genotype (Table S4). Further-
more, adjustment for maternal smoking quantity did not affect our
results (Table S5). Additional adjustment for maternal age, body
mass index at enrollment, parity, educational level and alcohol
consumption slightly attenuated the effect of maternal rs1051730,
although the directions of the effects remained similar (Table S6).
In these fully adjusted models, the interaction of maternal smoking
and genotype remained significant in third trimester of pregnancy.
Discussion
Main findings
Results from this prospective population-based cohort study
suggest that maternal genotype of the common genetic variant,
rs1051730, located within the 15q25 nicotinic acetylcholine
receptor gene cluster (CHRNA5-CHRNA3-CHRNB4), influences
the susceptibility of impaired fetal growth by maternal smoking.
Among mothers who smoked during pregnancy, the T-allele
resulted in smaller femur length and lower estimated fetal weight
from second trimester onwards.
Methodological considerations
An important strength of this study was the prospective design
and the large sample size of 3,563 participants being studied from
early pregnancy onwards. To our knowledge, this study is the first
study that examined the associations of maternal smoking during
pregnancy, and rs1051730, with fetal growth characteristics in
different trimesters of pregnancy.
A potential limitation of our study is that information about
smoking during pregnancy was collected by questionnaires.
Although assessing smoking during pregnancy by questionnaire
seems to be a valid method, misclassification may occur [7]. To
overcome these limitations, previous studies have used biomarkers
Table 2. Cross-sectional associations of maternal rs1051730 genotype with fetal growth characteristics in different trimesters1
(n = 3,563).
Second trimester Third trimester Birth
Head circumference Head circumference Head circumference
Difference (95% CI) (mm) Difference (95% CI) (mm) Difference (95% CI) (mm)
Total Group N=3,546 20.26 (20.56 to 0.04) 0.11 (20.33 to 0.55) 0.16 (20.63 to 0.95)
Non-smokers N= 2,940 20.23 (20.55 to 0.10) 0.23 (20.25 to 0.71) 0.31 (20.55 to 1.17)
Smokers N= 606 20.43 (21.21 to 0.35) 20.44 (21.55 to 0.66) 20.67 (22.71 to 1.37)
Interaction2 P= 0.62 P = 0.24 P = 0.39
Femur length Femur length Body length
Difference (95% CI) (mm) Difference (95% CI) (mm) Difference (95% CI) (mm)
Total Group N=3,549 0.00 (20.09 to 0.09) 20.01 (20.12 to 0.11) 0.33 (20.77 to 1.42)
Non-smokers N= 2,943 0.04 (20.05 to 0.14) 0.08 (20.04 to 0.20) 0.82 (20.38 to 2.02)
Smokers N= 606 20.23 (20.45 to 20.00)* 20.41 (20.69 to 20.13)** 22.61 (25.32 to 0.11)
Interaction2 P= 0.03 P,0.01 P = 0.04
Estimated fetal weight Estimated fetal weight Weight
Difference (95% CI) (g) Difference (95% CI) (g) Difference (95% CI) (g)
Total Group N=3,563 0.28 (21.88 to 2.43) 3.05 (26.23 to 12.32) 15.95 (25.59 to 37.48)
Non-smokers N= 2,953 1.36 (20.99 to 3.71) 10.37 (0.22 to 20.51)* 26.81 (3.05 to 50.57)*
Smokers N= 610 25.36 (210.73 to 0.01) 232.66 (255.36 to 29.97)** 238.13 (289.16 to 12.90)
Interaction2 P= 0.02 P,0.01 P = 0.03
1Effect estimates (with 95% confidence interval) reflect the differences in each growth characteristic for each additional copy of the T-allele of rs1051730 (assuming an
additive model).
2Interaction term=maternal genotype6smoking status.
*P-value,0.05;
**P-value,0.01.
All analyses were adjusted for gestational age at visit and sex. Analyses in the total group were additionally adjusted for smoking status (yes, no). Birth length and head
circumference at birth were additionally adjusted for source of the birth measurements.
doi:10.1371/journal.pone.0034584.t002
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of tobacco exposure, including cotinine -a metabolite of nicotine-
in maternal urine samples [8–9]. However, it has been
demonstrated that use of cotinine levels is not superior to the
use of self-reporting questionnaires in studying the effect of
maternal smoking in pregnancy on birth weight [10]. In general,
confounding is not likely to be a major issue in gene - outcome
association studies. The unadjusted and adjusted models focused
on the associations of rs1051730 genotype with fetal growth
characteristics did not show large differences in effect estimates.
However, smoking quantity might be a relevant confounder in our
study, since rs1051730 is known to be associated with smoking
quantity [4]. We adjusted the analyses for the number of cigarettes
smoked per day reported in first trimester, which did not change
the effect estimates. Furthermore, in our population of mothers
who smoked during pregnancy, smoking quantity was not
associated with rs1051730 genotype in neither first, second nor
third trimester. We also performed a sensitivity analysis using
second and third trimester smoking quantity instead of first
trimester smoking quantity in the models, which did not alter our
results. Therefore it seems unlikely that smoking quantity has
biased our results.
Another potential limitation could be that women who quitted
smoking when pregnancy was known (first trimester only) were
considered as non-smokers in our analyses. This could have
resulted in biased effect estimates if fetal growth would be different
between quitted smokers and non-smokers. However, we have
previously reported that first trimester smoking only does not affect
second and third trimester fetal growth [11]. We performed a
sensitivity analysis in which we excluded women who quitted
smoking in first trimester, which did not change our results (data
not shown).
We established gestational age by ultrasound. By using this
method, growth variation of the fetal characteristics used for
pregnancy dating is assumed to be zero. In our study, first
trimester crown-rump length and biparietal diameter were used
for pregnancy dating but not for assessing fetal growth. Since
pregnancy dating characteristics and growth characteristics are
correlated throughout pregnancy, growth variation in head
circumference, abdominal circumference, and femur length may
be reduced by dating the pregnancy on the other fetal
characteristics. This may have led to underestimation of our effect
estimates. However, we expect this effect to be small in our results.
This underestimation will consequently be lowest in women
included in the first trimester (54.7% of the population for
analysis). We performed a sensitivity analysis using only these
women, but results did not change (data not shown).
Maternal rs1051730 genotype, smoking during
pregnancy and fetal growth
The effects of maternal smoking status during pregnancy on
fetal growth have been studied previously, showing that among
mothers who continued smoking during pregnancy, children had
smaller femur length from second trimester onwards and smaller
head circumferences from third trimester onwards, as compared to
children from mothers who did not smoke during pregnancy [11].
As compared to children of mothers who did not smoke during
pregnancy, those of mothers who smoked during pregnancy have
a 100 to 200 grams lower birth weight [1]. This fetal growth
restriction might be caused by developmental adaptations in
placental vasculature and adaptations in fetal arterial resistance. A
study that investigated these adaptations showed an increased
umbilical resistance artery pulsatility index (PI) in pregnant women
who smoked, which indicates higher feto-placental resistance.
Also, a higher umbilical artery PI was associated with lower
estimated fetal weight and birth weight [12].
The effects of maternal smoking on fetal growth are known to
differ between individuals. We have previously demonstrated that
maternal first trimester folic acid supplementation use reduces the
adverse effects of maternal smoking during pregnancy on fetal
growth [13]. Differences in effects of maternal smoking on fetal
growth might also be explained by maternal genetic variation. We
hypothesized that maternal genotype of rs1051730 modifies the
association of maternal smoking during pregnancy with fetal
growth. The T-allele of rs1051730 is associated with higher
smoking quantity and higher nicotine levels in adults [4–5,14]. A
previous study showed that children from mothers who smoked
during pregnancy, had a tendency towards a 28 grams lower birth
weight per T-allele. No association was found among mothers who
did not smoke during pregnancy [6]. In line with this previous
study, we observed that among mothers who smoked during
pregnancy, the T-allele resulted in smaller femur length and lower
estimated fetal weight from second trimester onwards. We did not
observe any effect on fetal head circumference. The effects of
maternal smoking in fetal head circumference seem not to be
affected by rs1051730. Our results also suggest that rs1051730
does not have a direct effect on birth weight, but needs
environmental factors to exert its effect. Surprisingly, among
non-smokers, we found a positive effect on fetal weight with each
copy of the risk allele. We can not clearly explain this finding. It
might me hypothesized that specific gene-environmental interac-
tions, such as DNA methylation, changes the effects of specific
genetic variants [15]. In a recent meta-analysis, the risk allele of
rs1051730 was associated with a lower body mass index among
smokers, while some studies of this meta-analysis showed a higher
body mass index among non-smokers with the risk allele.
However, the overall effect of the meta-analysis showed no effect
of genotype among non-smokers [16]. We think that further
research is necessary to explore the different effects of risk alleles of
rs1051730 on various health outcomes among both smokers and
non-smokers.
The mechanism through which rs1051730 modifies the
associations between maternal smoking and fetal growth is yet
unknown. Rs1051730 is located in the nicotinic acetylcholine
receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) on chromo-
some 15q25. This locus has been investigated previously and
common genetic variants in high linkage disequilibrium with
rs1051730 (HapMap r2.0.8) were associated with higher
circulating cotinine levels, but not with number of cigarettes
smoked per day [14]. A previous study that assessed the
association of rs1051730 with the risk of lung cancer, observed
that subjects with the T-allele had higher mean nicotine
equivalents. In this study, the T-allele seemed to behave as a
dominant model after adjustment for smoking quantity [5]. The
authors therefore concluded that T-allele carriers extract a greater
amount of nicotine per cigarette and are exposed to a higher
internal dose of tobacco-specific nitrosamine, as compared to
Figure 1. Effect of maternal genotype and smoking status on fetal growth characteristics (SD scores)1. 1Values are based on repeated
linear regression models and reflect the differences in growth in gender and gestational age specific standard deviation scores (SDS) between the
number of risk alleles and smoking status compared to the reference group (genotype G/G, non-smokers). Estimates are given in the Supplementary
Table S2. *P-value,0.05; **P-value,0.01. (Figure 1a = head circumference growth, Figure 1b = length growth, Figure 1c =weight growth).
doi:10.1371/journal.pone.0034584.g001
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subjects without the T-allele [5]. Whether this is caused by more
intense smoking or by a change in the nicotine metabolism, is not
clear yet. Other studies suggested an additive genetic model for the
T-allele of rs1051730 [6,14], which was also most compliant with
our data. Thus our results suggest that children of mothers who
smoked during pregnancy are exposed to higher levels of nicotine
when the mother has a T-allele of rs1051730. Therefore, these
children might be more susceptible to the adverse effects of
maternal smoking during pregnancy. Further research is necessary
to determine the exact mechanism and underlying genetic model.
Gene-environment interaction studies are of increasing impor-
tance in modern medicine. Although smoking cessation should be
advised to all pregnant women, a genetic risk profile might help us
to target more effectively those at higher risk of growth retardation
and adverse pregnancy outcomes. Further research is needed to
identify groups at risk and develop new preventive strategies.
Conclusions
Our results suggest that maternal genotype of the 15q25 variant
rs1051730 influences the susceptibility of impaired fetal growth in
length and weight by maternal smoking. This association of
rs1051730 with fetal growth was present in mothers who
continued smoking during pregnancy, but not in mothers who
did not smoke during pregnancy. These results should be
considered as hypothesis generating and indicate the need for
large-scale genome wide association studies focusing on gene –
fetal smoke exposure interactions.
Materials and Methods
Design
This study was embedded in the Generation R Study, a
population-based prospective cohort study from early fetal life
onwards in Rotterdam, the Netherlands, which has been described
previously [17–18]. Enrollment was aimed at early pregnancy but
was allowed until delivery. Extensive assessments focused on fetal
growth and its main determinants were performed in each
trimester of pregnancy. All children were born between April
2002 and January 2006. The study has been approved by the
Medical Ethical Committee of the Erasmus Medical Center in
Rotterdam (MEC 198.782/2001/31). Written informed consent
was obtained from all participants.
Population for analysis
In total, 4,716 mothers of European ancestry (86% Dutch, 14%
other European) were included during pregnancy, of whom 3,862
mothers had a singleton live birth and had genotype of rs1051730
available. We had smoking status during pregnancy and fetal
ultrasounds available in 3,563 (92.3%) of these mothers. A
participant flow chart is given in Figure 2.
Maternal smoking status
Information about maternal smoking status during pregnancy
was obtained by postal questionnaires sent in first, second and
third trimester. Response rates for these questionnaires were 91%,
80% and 77%, respectively [18]. Maternal smoking at enrollment
was assessed in the first questionnaire by asking the mother
whether she smoked during the pregnancy (no, yes, until
pregnancy was known). In the second and third trimester
questionnaires, the mothers were asked whether they had smoked
(no, yes) during second and third trimester, respectively. Mothers
who reported to have smoked until pregnancy was known (first
trimester only) were considered as non-smokers. Mothers who
reported smoking in the second or third questionnaire, were
considered as mothers who continued smoking during pregnancy
[11]. Among mothers who continued smoking, the number of
cigarettes was classified into the following categories: less than 5
cigarettes per day, 5–10 cigarettes per day and more than 10
cigarettes per day.
Genotyping
Maternal DNA was extracted from whole blood samples.
Genotyping of the G.T substitution of rs1051730 in mothers was
performed using TaqMan allelic discrimination assay (Applied
Biosystems, Foster City, CA, USA). Child DNA was isolated from
cord blood. Genotyping was carried out using the Illumina 610 k
Quad arrays. The frequency distribution of maternal rs1051730
genotype did not deviate from the Hardy-Weinberg equilibrium in
subjects with European ancestry (GG: 45.4%, GT: 43.1%, TT:
11.6%, P-value= 0.78). Distribution of fetal genotype was similar
(GG: 47.3%, GT: 41.8%, TT: 10.8%, P-value = 0.73).
Fetal growth and birth outcomes
Fetal ultrasound examinations were carried out in two
dedicated research centers in each trimester of pregnancy.
Reliability and reproducibility of these ultrasound examinations
was tested in early pregnancy and was very good (Interobserver
intraclass correlation coefficients above 0.988 for all fetal
characteristics and interobserver coefficient of variation all
between 2.4% and 3.8%) [19]. Fetal ultrasound examinations
were used for both establishing gestational age in early pregnancy
and assessing second and third trimester fetal growth character-
istics. These methods have previously been described in detail
[18]. Establishing gestational age by the first day of the last
menstrual period is not reliable for a variety of reasons, including
the large number of women who do not know their exact date,
have irregular menstrual cycles or amenorrhea, use oral
contraceptive pills or bleed in early pregnancy [20–21]. Pregnancy
dating curves were constructed for subjects with complete data on
gestational age measured by ultrasonography and the last
menstrual period [21]. Crown-rump length was used for
pregnancy dating up to until a gestational age of 12 weeks and 5
days (crown-rump length smaller than 65 mm) and biparietal
diameter thereafter (gestational age from 12 weeks and 5 days
onwards, biparietal diameter larger than 23 mm). Second and
third trimester growth measurements (head circumference,
abdominal circumference and femur length) were measured to
the nearest millimeter using standardized ultrasound procedures
[22]. Estimated fetal weight was calculated using the formula by
Hadlock [23]. Gestational age adjusted standard deviation scores
were constructed for all fetal growth measurements based on
reference growth curves from the whole study population [21].
Information on date of birth, sex and birth anthropometrics (head
circumference, length and weight) was obtained from community
midwife and hospital registries. Gestational age and sex-adjusted
standard deviation scores for birth anthropometrics were con-
structed using growth standards from Usher and McLean [24].
Because head circumference and length were not routinely
measured at birth, missing birth measures were completed with
data from the first month visit at the routine child health center.
Of all measurements, 32% and 19% were based on the first month
visit for head circumference and birth length, respectively. No
differences in genotype between children with measurements at
birth and those with measurements at child health center were
observed (Chi-square tests: P=0.67 for head circumference and
P=0.51 for birth length).
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Covariates
Maternal age and information about maternal educational level
and parity was obtained by a questionnaire at enrollment in the
study. Maternal alcohol consumption habits were assessed by
questionnaires in each trimester. Maternal anthropometrics,
including height and weight, were measured without shoes and
heavy clothing and body mass index (BMI) was calculated
(weight/height2 [kg/m2]) at enrollment [25].
Statistical analysis
Differences in basic characteristics between mothers who did
not smoke and who smoked during pregnancy were assessed by
using a Student T-test for continuous variables and Chi-square
tests for categorical variables. We performed cross-sectional
analyses using linear regression models to assess the associations
of the maternal risk allele (T-allele of rs1051730) with fetal growth
characteristics in second and third trimester (head circumference,
femur length, estimated fetal weight) and at birth (head
circumference, body length, weight). Based on previous studies,
we considered an additive model, but performed a sensitivity
analysis using a T-dominant model. All other analyses were based
on an additive model and the effect estimates reflect the effect for
each additional copy of the risk allele. Analyses were performed in
the total group, and in strata of mothers who did not smoke during
pregnancy and mothers who smoked during pregnancy. We tested
the interaction between maternal smoking and maternal genotype,
to assess whether the associations of maternal smoking with fetal
growth were modified by the T-allele of rs1051730. All models
were adjusted for sex and gestational age at visit. Analyses in the
total population were adjusted for smoking status. To assess
possible confounding effects, we additionally adjusted for first
trimester smoking quantity as a covariate. Next, a fully adjusted
model was explored, with further adjustment for maternal age,
body mass index at enrollment, parity, educational level and
alcohol consumption. The regression models with neonatal head
circumference and length as outcome were additionally adjusted
for postconceptional age (gestational age at birth for measurements
at birth or gestational age at birth plus postnatal age for
measurement from the child health centers) and for the source
of the measurement (birth or child health center). We repeated the
analyses for fetal genotype.
The associations of smoke status, rs1051730 genotype and
longitudinally measured fetal growth were analyzed using
unbalanced repeated measurement regression models. The
repeatedly measured outcome data for this analysis were the
gender and gestational age adjusted SD scores. These models take
Figure 2. Flow chart of participants included for analysis.
doi:10.1371/journal.pone.0034584.g002
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the correlation between repeated measurements of the same
participant into account and allow for incomplete outcome data
[26]. We have used a fixed effects model without higher order
terms. This approach uses the exogenous sampling maximum
likelihood to assess the best model to calculate the effect estimates.
The genotype categories of non-smokers and smokers categories
were included in these models as intercept and as an interaction
term with gestational age. Each individual could have a maximum
of three measurements per growth characteristic available. The
analyses were based on 3,563 subjects with in total 9,751, 9,843
and 10,405 measurements for head circumference, length, and
weight, respectively. For all three growth characteristics, the
minimum number of measurements was 1, maximum 3 and
median was 3 (90% range 2–3) for head circumference, length,
and weight. The outcomes reflect the differences in growth in
gender and gestational age specific standard deviation scores
(SDS). The repeated measurement analysis was performed using
the Statistical Analysis System version 9.2 (SAS, Cary, NC),
including the Proc Mixed module for unbalanced repeated
measurements. All other analyses were performed using the
Statistical Package of Social Sciences for Windows (SPSS Inc,
Chicago, IL, USA), version 17.0.
Supporting Information
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(n=3,561). 1Effect estimates (with 95% confidence interval)
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risk alleles (assuming a dominant model). 2Interaction term=ma-
ternal genotype6smoking status. *P-value,0.05; **P-value,0.01.
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adjusted for smoking status (yes, no). Birth length and head
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Table S4 Cross-sectional associations of fetal rs1051730
genotype with fetal growth characteristics in different
trimesters (adjusted for maternal genotype)1 (n=1,960).
1Effect estimates (with 95% confidence interval) reflect the
differences in phenotype for each additional copy of the T-allele
of rs1051730 (assuming an additive model). 2Interaction term= -
fetal genotype6smoking status. *P-value,0.05; **P-value,0.01.
All analyses were adjusted for maternal rs1051730 genotype,
gestational age at visit and sex. Analyses in the total group were
additionally adjusted for smoking status (yes, no). Birth length and
head circumference at birth were additionally adjusted for source
of the birth measurements.
(DOC)
Table S5 Cross-sectional associations of maternal
rs1051730 genotype with fetal growth characteristics in
different trimesters1 (n= 3,561). 1Effect estimates (with 95%
confidence interval) reflect the differences in phenotype for each
additional copy of the T-allele of rs1051730 (assuming an additive
model). 2Interaction term=maternal genotype6smoking status.
*P-value,0.05; **P-value,0.01. All analyses were adjusted for
gestational age at visit, sex and smoking quantity. Analyses in the
total group were additionally adjusted for smoking status (yes, no).
Birth length and head circumference at birth were additionally
adjusted for source of the birth measurements.
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Table S6 Cross-sectional associations of maternal
rs1051730 genotype with fetal growth characteristics in
different trimesters1 (fully adjusted model n=3,521).
1Effect estimates (with 95% confidence interval) reflect the
differences in phenotype for each additional copy of the T-allele
of rs1051730 (assuming an additive model). 2Interaction term= -
maternal genotype6smoking status. *P-value,0.05; **P-val-
ue,0.01. All analyses were adjusted for gestational age at visit,
sex, maternal age, BMI at enrollment, parity, educational level,
alcohol use and smoking quantity. Analyses in the total group were
additionally adjusted for smoking status (yes, no). Birth length and
head circumference at birth were additionally adjusted for source
of the birth measurements.
(DOC)
Acknowledgments
The Generation R Study is conducted by the Erasmus Medical Center in
close collaboration with the School of Law and Faculty of Social Sciences
of the Erasmus University Rotterdam, the Municipal Health Service
Rotterdam area, Rotterdam, the Rotterdam Homecare Foundation,
Rotterdam and the Stichting Trombosedienst & Artsenlaboratorium
Rijnmond (STAR), Rotterdam. We gratefully acknowledge the contribu-
tion of parents and children, general practitioners, hospitals, midwives and
pharmacies in Rotterdam.
Author Contributions
Conceived and designed the experiments: EL HT RB VJ. Performed the
experiments: EL HT RB. Analyzed the data: EL HT RB. Contributed
reagents/materials/analysis tools: ES AH VJ. Wrote the paper: EL HT RB
ES AH VJ.
References
1. Jaddoe VW, Troe EJ, Hofman A, Mackenbach JP, Moll HA, et al. (2008) Active
and passive maternal smoking during pregnancy and the risks of low birthweight
and preterm birth: the Generation R Study. Paediatr Perinat Epidemiol
Mar;22(2): 162–71.
2. Varvarigou AA, Fouzas S, Beratis NG (2010) Effect of prenatal tobacco smoke
exposure on fetal growth potential. J Perinat Med Nov;38(6): 683–7.
3. Freathy RM, Mook-Kanamori DO, Sovio U, Prokopenko I, Timpson NJ, et al.
(2010) Variants in ADCY5 and near CCNL1 are associated with fetal growth
and birth weight. Nat Genet May;42(5): 430–5.
4. Tobacco and Genetics consortium (2010) Genome-wide meta-analyses identify
multiple loci associated with smoking behavior. Nat Genet May;42(5): 441–7.
5. Le Marchand L, Derby KS, Murphy SE, Hecht SS, Hatsukami D, et al. (2008)
Smokers with the CHRNA lung cancer-associated variants are exposed to
15q25 Locus, Maternal Smoking and Fetal Growth
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e34584
higher levels of nicotine equivalents and a carcinogenic tobacco-specific
nitrosamine. Cancer Res Nov 15;68(22): 9137–40.
6. Freathy RM, Ring SM, Shields B, Galobardes B, Knight B, et al. (2009) A
common genetic variant in the 15q24 nicotinic acetylcholine receptor gene
cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of
women to quit smoking in pregnancy. Hum Mol Genet Aug 1;18(15): 2922–7.
7. Klebanoff MA, Levine RJ, Morris CD, Hauth JC, Sibai BM, et al. (2001)
Accuracy of self-reported cigarette smoking among pregnant women in the
1990s. Paediatr Perinat Epidemiol Apr;15(2): 140–3.
8. Hebel JR, Fox NL, Sexton M (1988) Dose-response of birth weight to various
measures of maternal smoking during pregnancy. J Clin Epidemiol 41(5): 483–9.
9. Wang X, Tager IB, Van Vunakis H, Speizer FE, Hanrahan JP (1997) Maternal
smoking during pregnancy, urine cotinine concentrations, and birth outcomes. A
prospective cohort study. Int J Epidemiol Oct;26(5): 978–88.
10. Haddow JE, Knight GJ, Palomaki GE, Kloza EM, Wald NJ (1987) Cigarette
consumption and serum cotinine in relation to birthweight. Br J Obstet
Gynaecol Jul;94(7): 678–81.
11. Jaddoe VW, Verburg BO, de Ridder MA, Hofman A, Mackenbach JP, et al.
(2007) Maternal smoking and fetal growth characteristics in different periods of
pregnancy: the generation R study. Am J Epidemiol May 15;165(10): 1207–15.
12. Geelhoed JJ, El Marroun H, Verburg BO, van Osch-Gevers L, Hofman A, et al.
(2011) Maternal smoking during pregnancy, fetal arterial resistance adaptations
and cardiovascular function in childhood. BJOG May;118(6): 755–62.
13. Bakker R, Timmermans S, Steegers EA, Hofman A, Jaddoe VW (2011) Folic
Acid supplements modify the adverse effects of maternal smoking on fetal
growth and neonatal complications. J Nutr Dec;141(12): 2172–9.
14. Timofeeva MN, McKay JD, Davey SG, Johansson M, Byrnes GB, et al. (2011)
Genetic Polymorphisms in 15q25 and 19q13 Loci, Cotinine Levels, and Risk of
Lung Cancer in EPIC. Cancer Epidemiol Biomarkers Prev Oct;20(10):
2250–61.
15. Freathy RM, Kazeem GR, Morris RW, Johnson PC, Paternoster L, et al. (2011)
Genetic variation at CHRNA5-CHRNA3-CHRNB4 interacts with smoking
status to influence body mass index. Ultrasound Obstet Gynecol 1996 Sep;8(3):
178–85.
16. Breton CV, Byun HM, Wenten M, Pan F, Yang A, et al. (2009) Prenatal
tobacco smoke exposure affects global and gene-specific DNA mehtylation.
Am J Respir Crit Care Med Sep 1;180(5): 462–7.
17. Jaddoe VW, Bakker R, van Duijn CM, van der Heijden AJ, Lindemans J, et al.
(2007) The Generation R Study Biobank: a resource for epidemiological studies
in children and their parents. Eur J Epidemiol 22(12): 917–23.
18. Jaddoe VW, van Duijn CM, van der Heijden AJ, Mackenbach JP, Moll HA, et
al. (2010) The Generation R Study: design and cohort update 2010.
Eur J Epidemiol Nov;25(11): 823–41.
19. Verburg BO, Mulder PG, Hofman A, Jaddoe VW, Witteman JC, et al. (2008)
Intra- and interobserver reproducibility study of early fetal growth parameters.
Prenat Diagn 2008 Apr;28(4): 323–31.
20. Tuno´n K, Eik-Nes SH, Grøttum P (1996) A comparison between ultrasound
and a reliable last menstrual period as predictors of the day of delivery in 15,000
examinations. Ultrasound Obstet Gynecol 1996 Sep;8(3): 178–85.
21. Verburg BO, Steegers EA, De Ridder M, Snijders RJ, Smith E, et al. (2008)
New charts for ultrasound dating of pregnancy and assessment of fetal growth:
longitudinal data from a population-based cohort study. Ultrasound Obstet
Gynecol Apr;31(4): 388–96.
22. Royal College of Obstetricians and Gynaecologists (2000) Routine ultrasound
screening in pregnancy: protocol. London, United Kingdom: RCOG Press.
23. Hadlock FP, Harrist RB, Carpenter RJ, Deter RL, Park SK (1984) Sonographic
estimation of fetal weight. The value of femur length in addition to head and
abdomen measurements. Radiology Feb;150(2): 535–40.
24. Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, et al. (1991) An
update of the Swedish reference standards for weight, length and head
circumference at birth for given gestational age (1977–1981). Acta Paediatr
Scand Aug–Sep;80(8–9): 756–62.
25. Ay L, Kruithof CJ, Bakker R, Steegers EA, Witteman JC, et al. (2009) Maternal
anthropometrics are associated with fetal size in different periods of pregnancy
and at birth. The Generation R Study. BJOG Jun;116(7): 953–63.
26. Goldstein H (1995) Multilevel statistical methods. 2nd ed Edward Arnold:
London.
15q25 Locus, Maternal Smoking and Fetal Growth
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e34584
